Drug firm Suven Life Sciences today said it has given exclusive license to Taro Pharmaceutical Industries to market its Malathion Lotion, used to teat scalp infection, in US, Canada and Mexico.
The company has granted an exclusive license and right to distribute and market its Malathion Lotion in USA, Canada and Mexico to Taro Pharmaceuticals North America Inc, a subsidiary of Taro Pharmaceutical Industries Ltd, Suven Life Sciences said in a statement.
"In consideration for the exclusive license and right to distribute and market Malathion Lotion USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated," it added.
Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.
Suven shares today closed at Rs 74.35 apiece on the BSE, up 1.50 per cent from previous close.
